Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2018

  • ID: 4482733
  • Report
  • 64 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Idorsia Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Orexin Receptor Type 2 - Pipeline Review, H1 2018'; Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Orexin receptor type 2 (Ox2R or OX2) also known as hypocretin receptor type 2, is a protein that is encoded by the HCRTR2 gene. OX2 is a G-protein coupled receptor expressed exclusively in the brain. OX2 binds both orexin A and orexin B neuropeptides. OX2 is involved in the central feedback mechanism that regulates feeding behavior.

The report 'Orexin Receptor Type 2 - Pipeline Review, H1 2018' outlays comprehensive information on the Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 4 and 4 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Insomnia, Narcolepsy, Sleep Disorders, Dementia Associated With Alzheimer's Disease and Major Depressive Disorder.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
  • The report reviews Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Idorsia Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • MORE
Introduction

Report Coverage

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Overview

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Companies Involved in Therapeutics Development

Actelion Pharmaceuticals Ltd

Eisai Co Ltd

Evotec AG

Heptares Therapeutics Ltd

Idorsia Ltd

Johnson & Johnson

Merck & Co Inc

OptiNose US Inc

Takeda Pharmaceutical Co Ltd

Yangtze River Pharmaceutical Group

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Drug Profiles

ACT-541468 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DORA-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-6641 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lemborexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPN-021 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

seltorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 2 Receptor for Sleep Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Orexin 1 and 2 Receptors for Insomnia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

suvorexant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-925 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YNT-185 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Dormant Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Discontinued Products

Orexin Receptor Type 2 (Hypocretin Receptor Type 2 or HCRTR2) - Product Development Milestones

Featured News & Press Releases

Mar 07, 2018: Eisai and Purdue Pharma Announce Positive Top line Results From Key Clinical Studies of Lemborexant

Dec 21, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients with Major Depressive Disorder

Dec 07, 2017: Eisai and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies at ACNP Annual Meeting

Dec 06, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

Oct 31, 2017: Eisai To Present Latest Data On lemborexant At 10th Clinical Trials On Alzheimer's Disease

Sep 05, 2017: Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) as Adjunctive Therapy in Patients With Major Depressive Disorder

Jul 28, 2017: ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia

Oct 28, 2016: Eisai To Initiate Phase II Clinical Study Of Dual Orexin Receptor Antagonist Lemborexant In Patients With Irregular Sleep-Wake Rhythm Disorder And Dementia

Jul 07, 2016: Actelion To Enter Phase II Clinical Development With New Dual Orexin Receptor Antagonist In Patients With Insomnia

Jun 01, 2016: Minerva Neurosciences to Present data on MIN-

Mar 11, 2016: Minerva Neurosciences Announces Positive Top Line Results From Phase Ib Clinical Trial in Major Depressive Disorder With MIN-

Feb 01, 2016: Minerva Neurosciences Announces Top Line Data From MIN-202 Phase I Clinical Study in Japanese Patients

Feb 01, 2016: OptiNose Announces Pipeline Project to Evaluate Nose-to-Brain Application of Bi-Directional Breath Powered Technology Selected for Norwegian Government Funding

Jan 11, 2016: Minerva Neurosciences Announces Favorable Top Line Results from MIN-202 Phase 2A Clinical Trial in Insomnia Disorder

Dec 09, 2015: Minerva Provides Year-End Update on Clinical Trial with Central Nervous System Product Candidate MIN-

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Actelion Pharmaceuticals Ltd, H1 2018

Pipeline by Eisai Co Ltd, H1 2018

Pipeline by Evotec AG, H1 2018

Pipeline by Heptares Therapeutics Ltd, H1 2018

Pipeline by Idorsia Ltd, H1 2018

Pipeline by Johnson & Johnson, H1 2018

Pipeline by Merck & Co Inc, H1 2018

Pipeline by OptiNose US Inc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Pipeline by Yangtze River Pharmaceutical Group, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Actelion Pharmaceuticals Ltd
  • Eisai Co Ltd
  • Evotec AG
  • Heptares Therapeutics Ltd
  • Idorsia Ltd
  • Johnson & Johnson
  • Merck & Co Inc
  • OptiNose US Inc
  • Takeda Pharmaceutical Co Ltd
  • Yangtze River Pharmaceutical Group
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll